Nkgen Biotech Inc (NKGN)

$0.26 +0.07 (35.91%)
Market Cap 8.60M
Revenue (ttm) 0.00
Net Income (ttm) -82.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.10
Volume 1,562,500
Avg Vol 4,676,562
Day's Range N/A - N/A
Shares Out 44.95M
Stochastic %K 0%
Beta 0.45
Analysts Strong Buy
Price Target N/A

Company Profile

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HE...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 396 6830
Address:
3001 Daimler Street, Santa Ana, United States
Picklerinthekitchen
Picklerinthekitchen Mar. 13 at 6:49 PM
$NKGN well fun while it lasted at .20 !
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Mar. 11 at 1:32 AM
$NKGN
0 · Reply
RupertDCat
RupertDCat Mar. 10 at 2:05 PM
$NKGN https://www.stocktitan.net/news/NKGN/nk-gen-biotech-to-present-integrated-phase-1-clinical-and-biomarker-2vh2ir2k3p2n.html
0 · Reply
MTBolz
MTBolz Mar. 8 at 7:26 AM
$NKGN
0 · Reply
BCINU
BCINU Mar. 5 at 10:37 PM
$NKGN bullish it has a great future
0 · Reply
dmb1879
dmb1879 Mar. 5 at 8:03 PM
$NKGN
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Feb. 20 at 12:32 AM
$NKGN
0 · Reply
Pedro1979
Pedro1979 Feb. 17 at 9:29 PM
$NKGN I wish you and your team all the best and I believe in NKGen. Greetings from Austria. Peter
0 · Reply
dmb1879
dmb1879 Feb. 17 at 9:27 PM
$NKGN
0 · Reply
BCINU
BCINU Feb. 17 at 7:31 PM
$NKGN Paul Song announced: Paul Y. Song, MD 5d As my mom worked for nearly 25 years as the educational director of the Newark, NJ Head Start program, it is especially meaningful for me to be back in Newark at University Hospital (Rutgers Health) where we will soon open our first clinical trial site in the NY/NJ metropolitan region. As this center cares for an ethnically diverse disadvantaged community, I am grateful to have this opportunity to offer our #troculeucel NK cell therapy for neurodegenerative disease to further their mission and to work with Dr. Jack Tsao and his amazing staff.
1 · Reply
Latest News on NKGN
No data available.
Picklerinthekitchen
Picklerinthekitchen Mar. 13 at 6:49 PM
$NKGN well fun while it lasted at .20 !
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Mar. 11 at 1:32 AM
$NKGN
0 · Reply
RupertDCat
RupertDCat Mar. 10 at 2:05 PM
$NKGN https://www.stocktitan.net/news/NKGN/nk-gen-biotech-to-present-integrated-phase-1-clinical-and-biomarker-2vh2ir2k3p2n.html
0 · Reply
MTBolz
MTBolz Mar. 8 at 7:26 AM
$NKGN
0 · Reply
BCINU
BCINU Mar. 5 at 10:37 PM
$NKGN bullish it has a great future
0 · Reply
dmb1879
dmb1879 Mar. 5 at 8:03 PM
$NKGN
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Feb. 20 at 12:32 AM
$NKGN
0 · Reply
Pedro1979
Pedro1979 Feb. 17 at 9:29 PM
$NKGN I wish you and your team all the best and I believe in NKGen. Greetings from Austria. Peter
0 · Reply
dmb1879
dmb1879 Feb. 17 at 9:27 PM
$NKGN
0 · Reply
BCINU
BCINU Feb. 17 at 7:31 PM
$NKGN Paul Song announced: Paul Y. Song, MD 5d As my mom worked for nearly 25 years as the educational director of the Newark, NJ Head Start program, it is especially meaningful for me to be back in Newark at University Hospital (Rutgers Health) where we will soon open our first clinical trial site in the NY/NJ metropolitan region. As this center cares for an ethnically diverse disadvantaged community, I am grateful to have this opportunity to offer our #troculeucel NK cell therapy for neurodegenerative disease to further their mission and to work with Dr. Jack Tsao and his amazing staff.
1 · Reply
RupertDCat
RupertDCat Feb. 15 at 2:24 AM
$NKGN https://www.linkedin.com/posts/paul-y-song-md-7664147_troculeucel-activity-7427762509262159872-g_kn?utm_source=share&utm_medium=member_ios&rcm=ACoAAAm5LksBlME8Y5PuvN1rjw1zbzyfmTRN8Pc
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Feb. 14 at 2:44 AM
$NKGN
0 · Reply
whereisthebull50
whereisthebull50 Feb. 13 at 3:17 PM
$NKGN Now it’s very hard to believe anything This company says. They can’t keep their own words. Enrollment supposed to be completed by last year June. Trading on otcqx or nasdaq supposed to be started by Dec last year, Phase 2a initial result supposed to be by Dec last year. Now in a recent interview CEO said results in the middle of this year. Why do they need to do this ? Hope it’s not an another version of SAVA.
1 · Reply
BCINU
BCINU Feb. 11 at 10:25 PM
$NKGN good news and this is a definite short squeeze and if they get reinstated on Nasdaq it will squeeze
1 · Reply
whereisthebull50
whereisthebull50 Feb. 5 at 11:35 PM
$NKGN 41m warrant to CEO in the name of private placement during financial distress 😳
0 · Reply
Picklerinthekitchen
Picklerinthekitchen Feb. 4 at 12:44 PM
$NKGN
0 · Reply
whereisthebull50
whereisthebull50 Feb. 3 at 7:55 PM
$NKGN company releases news on almost everything other than phase2a or trading stock on otc/nasdaq. whats exactly going on?
1 · Reply
dmb1879
dmb1879 Jan. 27 at 3:17 PM
$NKGN up to $.13! We're eating today!
1 · Reply
Picklerinthekitchen
Picklerinthekitchen Jan. 22 at 3:05 PM
$NKGN trial on track , short term 25m financing in place , something positive in the works.
0 · Reply
BCINU
BCINU Jan. 22 at 2:54 PM
$NKGN this is good news
0 · Reply
BCINU
BCINU Jan. 22 at 2:53 PM
$NKGN NKGen Biotech, Inc. (OTC: NKGN) announces Bruce L. Miller, M.D., a globally recognized dementia expert, joined its Scientific Advisory Board. His expertise in neurodegenerative disease strengthens NKGen’s clinical programs and exploration of FTD. http://bit.ly/4pTjeWW $NKGN
0 · Reply
Abdullah5566
Abdullah5566 Jan. 21 at 5:23 PM
$NKGN it seems that game is over 🥲🥲💔
1 · Reply